Evommune Announces $125 Million Private Placement

Core Viewpoint - Evommune, Inc. has announced a securities purchase agreement to sell 4,494,279 shares of its common stock in a private placement to a select group of mutual funds and healthcare institutional investors [1] Group 1: Company Overview - Evommune, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies targeting chronic inflammatory diseases [1] Group 2: Financial Details - The private placement involves the sale of 4,494,279 shares of common stock [1]